Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes
Geeta Geeta Sharma1, Ines Mota2, Luca Mologni3,4
1Department of Medicine and Surgery, University of Milano-Bicocca, Monza 20900, Italy. geeta.geeta@unimib.it.
Abstract:
Anaplastic lymphoma kinase (ALK) is a validated molecular target in several ALK-rearranged malignancies, particularly in non-small-cell lung cancer (NSCLC), which has generated considerable interest and effort in developing ALK tyrosine kinase inhibitors (TKI). Crizotinib was the first ALK inhibitor to receive FDA approval for ALK-positive NSCLC patients treatment. However, the clinical benefit observed in targeting ALK in NSCLC is almost universally limited by the emergence of drug resistance with a median of occurrence of approximately 10 months after the initiation of therapy. Thus, to overcome crizotinib resistance, second/third-generation ALK inhibitors have been developed and received, or are close to receiving, FDA approval. However, even when treated with these new inhibitors tumors became resistant, both in vitro and in clinical settings. The elucidation of the diverse mechanisms through which resistance to ALK TKI emerges, has informed the design of novel therapeutic strategies to improve patients disease outcome. This review summarizes the currently available knowledge regarding ALK physiologic function/structure and neoplastic transforming role, as well as an update on ALK inhibitors and resistance mechanisms along with possible therapeutic strategies that may overcome the development of resistance.
Insights
Anaplastic lymphoma kinase (ALK) inhibitors effectively treat ALK-rearranged cancers like non-small-cell lung cancer (NSCLC). However, drug resistance frequently emerges, necessitating new strategies to overcome treatment limitations.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Anaplastic lymphoma kinase (ALK) is a key target in ALK-rearranged cancers, notably non-small-cell lung cancer (NSCLC).
- ALK tyrosine kinase inhibitors (TKIs) like crizotinib were developed to target these malignancies.
- Acquired resistance to ALK TKIs is a significant clinical challenge, limiting long-term patient benefit.
Purpose of the Study:
- To review the physiological role and oncogenic function of ALK.
- To provide an update on ALK inhibitors, including second and third-generation agents.
- To summarize resistance mechanisms and explore therapeutic strategies to overcome TKI resistance.
Main Methods:
- Literature review of ALK function, inhibitors, and resistance mechanisms.
- Analysis of clinical and preclinical data on ALK-targeted therapies.
- Synthesis of information on emerging resistance pathways and novel therapeutic approaches.
Main Results:
- ALK plays a critical role in normal development and cancer transformation.
- Multiple generations of ALK TKIs have been developed, showing initial efficacy but eventual resistance.
- Diverse resistance mechanisms, both intrinsic and acquired, have been identified.
- Emerging resistance necessitates the development of next-generation inhibitors and combination strategies.
Conclusions:
- Understanding ALK's role and resistance mechanisms is crucial for improving NSCLC treatment.
- Novel therapeutic strategies are needed to overcome acquired resistance to ALK TKIs.
- Continued research into ALK biology and drug development holds promise for better patient outcomes.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Resistivity
Resistance
Gene Therapy
Equivalent Resistance
Resistance and Conductance
Various factors impact the resistance of a conductor. Spiraling in stranded conductors increases their...


